Glial-neuronal interchange of amino acids was studied by 13C nuclear magnetic resonance spectroscopy of brain extracts from fluoroacetate-treated mice that received [1,2-l3C]acetate and [1-13C]glucose simultaneously, [13C]Ac
According to the commonly accepted idea of the glu tamate-glutamine cycle, glutamine is formed in glia and transferred to neurons as a precursor for transmitter glu tamate and ),-aminobutyric acid (GABA). After release during neurotransmission, glutamate and GABA are taken up by glial cells and converted to glutamine (Balazs et aI., 1970; Van den Berg, 1973) , Much of the evidence in favor of such a cycle has been obtained from studies in vitro. Evidence for a glutamine cycle in the brain includes the localization of glutamine synthetase in glial cells only (Martinez-Hernandez et aI., 1977) and its presence in glial processes in the vicinity of glutamater gic synapses (Derouiche and Frotcher, 1991) , The extra cellular level of glutamine is high in brain, -0,25 mmollL (Hagberg et aI., 1985) , and during inhibition of the glial tricarboxylic acid (TCA) cycle the level decreases (Paulsen and Fonnum, 1989) in agreement with exten sive glial export of glutamine under physiologic condi tions.
The role of glutamine as a precursor for transmitter amino acids has been more difficult to ascertain in vivo, e,g., with radiolabeled glutamine which only labeled GABA after prolonged intracerebral infusion (Thanki et aI., 1983) , Instead, several authors have used labeled acetate, which to a large extent is rapidly converted to glutamine by the intact brain (O'Neal and Koeppe, 1966; Van den Berg et aI., 1969) . The labeling of GABA from acetate has been interpreted to reflect transfer of labeled glutamine from glia to neurons (Van den Berg, 1973; Cerdan et aI., 1990; Hassel et aI., 1995) . There remains a need, however, to determine in vivo whether acetate is a substrate for glia only, or whether it may also be me tabolized by neurons, If acetate is a substrate for neurons, labeling of GABA from e 4 C]acetate or [ 13 C]acetate can not serve as an indicator of glial-neuronal transfer of glutamine, Uptake of glutamate and GABA by glia in vivo is suggested by the presence of transport proteins for GABA and glutamate in the glial plasma membrane (Ra dian et aI., 1990; Pines et aI., 1992; Storck et aI., 1992; Rothstein et aI., 1994) , by the elevated extracellular level of glutamate in brains of rats lacking glial glutamate transporters (Rothstein et aI., 1996) , and by the rapid labeling of glutamine when radiolabeled glutamate and GABA are injected into the brain (Berl et al., 1961; Berl and Purpura, 1966; Hassel et al., 1992) . It should be noted, however, that injection of radiolabeled glutamate and GABA does not reproduce normal neurotransmis sian, because to a large extent the injected amino acids may reach nonsynaptic brain tissue. As neuronal gluta mate and GABA are rapidly labeled from glucose (Cre mer, 1964; O'Neal and Koeppe, 1966; Van den Berg et al., 1969; Fitzpatrick et al., 1990) , labeling of glutamine from glucose could indicate transfer of glutamate and GABA from neurons to glia. However, labeling of glu tamine from [ 13 C]glucose or e 4 C]glucose may also re flect glial metabolism of glucose. To distinguish between the two routes for labeling of glutamine from glucose, the use of fluoroacetate, an inhibitor of aconitase of the glial TCA cycle (Clarke et al., 1970; Cheng et aI., 1972; Muir et aI., 1986) , seems attractive, as in the presence of this toxin, the labeling of glutamine from glucose should mainly reflect transfer of glutamate from neurons to glia.
The purpose of the present study was to determine to what degree glial uptake of amino acid transmitters takes place in vivo, and to what extent glutamine is a likely glial precursor of neuronal glutamate and GABA, using 13 C-labeled gJucose and acetate with 13 C nuclear mag netic resonance (NMR) spectroscopy. Therefore, it was also necessary to determine whether [ l3 C]acetate may be used as a specific marker for glial metabolism even in the large doses needed for l3 C NMR spectroscopy. These are important issues considering the possible use of 13 C_ labeled substrates in conjunction with 13 C NMR spec troscopy in the study of human cerebral metabolism (Gruetter et aI., 1994; Mason et aI. 1995) .
In the current study [1 ,2-l3 C] acetate was administered intravenously together with [1-13 C]glucose to awake mice, and brain extracts were analyzed by 13 C NMR spectroscopy and by gas chromatography/mass spec trometry (GC/MS). Coadministration of [l,2-13 C]acetate and [l-13 C]glucose has been used successfully in vitro to assess glial-neuronal interactions (Taylor et al., 1996) . Incorporation of the coupled 13 C atoms of [1,2-l3 C]acetate into amino acids gives rise to isotopomer patterns in the NMR spectra that are different from those obtained by incorporation of the single I3 C atom of r 1-13 C]glucose (Taylor et aI., 1996; Badar-Goffer and Bach elard, 1991) . The contribution of [l,2-13 C] acetate to the labeling of metabolites may therefore be distinguished from the labeling obtained from [1-l3 C]glucose. If ac etate is metabolized exclusively by glia, this allows de termination of the glial versus the neuronal contribution to the labeling of amino acids. Fluoroacetate was used to selectively inhibit glial TCA cycle activity to allow fur ther differentiation between the glial and neuronal for mation of amino acids.
MATERIALS AND METHODS

Materials
Female NMRI mice (Bomholt, Ry, Denmark), 30 g body weight, were caged in groups of 10 with free access to food and tap water, with a 12-hour light/dark cycle, a relative humidity of 50%, and a room temperature of 25°e. Before experiments the animals were fasted for 24 hours with free access to tap water. Sodium [1,2- 
Experimental protocols
Four experimental groups of mice were used. The animals were unanesthetized during the study. One group of mice (n = 8) was dosed with 0.3 mL of the solution containing the 13C_ labeled substrates. The injection was done in a tail vein and was completed in 5 seconds. Another group of animals (n = 7) received 0.25 mL of the fluoroacetate solution, corresponding to 100 mg fluoroacetate/kg body weight, intraperitoneally. This dose has previously been shown not to interfere with cerebral levels of ATP (Goldberg et ai., 1966) . At 15 minutes these animals received 0.3 mL of the solution containing the I3C_ (Peters, 1957; Brand et ai., 1973) . Because the enrichment of citrate could not be reliably quantified by NMR spectroscopy, these brain extracts were analyzed by GC/MS gas chromatography/mass spectrometry.
All animals were killed by cervical dislocation and decapi tation 15 minutes after injection of the I3C-Iabeled substrates.
The heads were immediately immersed in liquid N2, and blood (-500 f.1L) was collected from the severed vessels. The brains were removed in the frozen state, and were homogenized in 2 mL ice-cold perchloric acid, 7% (vol/vol). The homogenizer was rinsed with I mL double-distilled water that was added to the homogenate. Protein was removed by centrifugation (20,000g for 20 minutes), and the supernatant was neutralized with 9 mollL KOH. The precipitate, KCI04, was removed by centrifugation (20,000g for 20 minutes), and 300 f.1L (-10%) of the supernatant was used for determination of total amounts of amino acids, lactate, and glucose; the rest was lyophilized to dryness. Serum was obtained by centrifugation of blood samples at 5,000g for 5 minutes, and 10 f.1L serum was used to determine serum glucose. The rest was mixed with I mL 3.5% perchloric acid and frozen at -70°e. After centrifugation, neu tralization with KOH, and another centrifugation to remove KCI04, 1.2 mL of the supernatant was lyophilized to dryness.
The animals were handled in strict accordance with the insti tutional and national guidelines for animal research. with o-phthaldialdehyde (Sigma), using an LC-DB 18 column, 25 cm length, 4 mm inner diameter, 5 JLm pore size (Pharmacia Biotech, Uppsala, Sweden). The mobile phase was 75% 50 mmollL phosphate buffer, pH 5.25, and 25% methanol, chang ing gradually to 25% phosphate buffer and 75% methanol dur ing 20 minutes. a-Amino adipic acid (0.5 mmollL) was added 1: 1 to the samples as internal standard. A mixture of the amino acids of interest in equimolar concentration was run as an ex ternal standard. Citrate was measured spectrophotometric ally (UV 120 1, Shimadzu, Kyoto, Japan) using an enzymatic kit from Boehringer (Mannheim, Germany) (Cat. No. 139 076).
The content of glucose and lactate in extracts of brain and serum as well as the glucose concentration ip serum was mea sured by reflectance spectrophotometry using an Ektachem DT60 (Kodak, Rochester, NY, U.S.A.).
NMR spectroscopy
Proton-decoupled 125.7 MHz l3C NMR spectra were ob tained on a Bruker Avance DRX-500 spectrometer (Bruker, Zurich, Switzerland). Lyophilized samples were redissolved in 
Gas chromatography/mass spectrometry (Ge/MS)
Samples of neutralized perchloric acid extracts or plasma were adjusted to pH -2.5, dried under N2, and derivatized with N-methyl-N-t-butyldimethylsilyl trifluoroacetamide (Sigma) at 70°C (Mawhinney et aI., 1986) Atom percent excess of the various metabolites was determined after allowing for naturally abundant \3C and silicon (from silyl groups) as described by Biemann (1962) . This yielded the per cent singly labeled (M + I) and doubly labeled (M + 2) frag ments of the intermediates.
Statistics
Values are given as means ± SD. Differences between groups were analyzed by the two-tailed Student's t-test. Dif ferences in percent enrichments between carbon positions within a molecule or between molecules within the same ani mal were analyzed by the two-tailed paired Student's t-test.
RESULTS
Behavioral changes
Intravenous injection of acetate and glucose into con trol mice did not cause behavioral changes. Five minutes after injection of fluoroacetate the animals showed inter mittent "freezing" in a posture for 5 to 20 second, and they tended to lie down more than their untreated litter mates, At 10 minutes the animals would lie down, but could readily be awakened to walk about the cage for short distances, At 15 minutes, when the animals re ceived the intravenous injection, they appeared very somnolent and were not readily aroused. They would, however, resist being rolled over on the side. At this stage two of the seven animals had general convulsions that lasted for -5 s. The somnolent state, which com menced before the intravenous injection, lasted for ap proximately 5 minutes. Thereafter the animals became more alert, with short episodes of spontaneous walking. Respiration appeared unaffected, with a respiratory fre quency of 140 to 200 breaths/min, Throughout the time of exposure to the l3 C-labeled substrates, the animals were clearly affected by the fluoroacetate.
Effects of fluoroacetate on total levels of brain metabolites and on serum metabolites
Flouroacetate caused a 200% increase in the cerebral level of citrate and a 78% increase in the level of glucose (Table 1 ). The level of aspartate decreased by 32% and that of alanine increased by 120%, indicating shifts in the equilibria of aspartate and alanine aminotransferases. The other measured metabolites remained constant.
Fifteen minutes after injection of the I3 C-labeled sub strates, serum glucose was l3.1 ± 2.9 mmol/L in the control group and 14.7 ± 3.3 mmol/L in the fluoroacetate group (means ± SD, n = 8 and 7, respectively). The percent enrichment of glucose C-l was 40.9% ± 3.3% in controls and 38.9% ± 6.3% in flu oro acetate-treated ani mals as detected by GC/MS. 13 C Nuclear magnetic reso nance spectra of serum extracts showed single peaks of glucose C-l and lactate C-2 and C-3. No peaks of other isotopomers of [ \3 C]glucose were seen, which shows [l_ 13 C]Glucose gave a higher 13 C enrichment in glu tamate C-4 and GABA C-2 than in glutamine C-4, -12% in glutamate and GABA, and -6% in glutamine (Table  2 ). [1,2-13 C]Acetate, on the other hand, gave a higher l3 C enrichment in glutamine C-4 (-15%) than in gluta mate C-4 and GABA C-2 (4% to 5%) ( Table 3) . The glutamine C-4/glutamate C-4 enrichment ratio obtained with [1-I3 C]glucose was thus 0.54 ± 0.04. The ratio ob tained with [1,2-13 C]acetate was 3.4 ± l.6 (n = 8), con firming predominantly neuronal metabolism of [1-13 C]glucose and glial metabolism of [I ,2-13 Clacetate (see Discussion).
[1-I3 C]Glucose gave an enrichment of -8% in aspar tate C-2 and C-3 (Table 2) , whereas [1,2-13 C]acetate gave an enrichment of -2% in both carbon positions (Table 3 ). The percent enrichment of aspartate C-2 was not significantly different from the C-3 position with either of the two 13 C-Iabeled precursors.
Glucose C-l, which had a 13 C enrichment of approxi mately 30% (Table 2) , was the only carbon position of glucose that was visible in the spectra. [I ,2-13 C]Acetate was not present in the spectra.
Effects of fluoroacetate on the labeling of cerebral metabolites
In fluoroacetate-treated animals labeling of glutamine from [1,2-13 C]acetate was hardly detectable by NMR, as seen by the reduction of peaks representing [4,5-13 C]glutamine ( Fig. 1; Table 3 ). Likewise, [1,2-13 C]GABA, [l,2-13 C]aspartate, and [3,4_ 13 C]aspartate were not detected in the brain extracts of fluoroacetate treated animals, whereas [4,5-l3 C]glutamate was reduced by 68% ( Fig. I; Table 3 ), indicating preserved labeling of glial glutamate (Hassel et aI., 1992) . In contrast to the lack of labeling of glutamine C-4 from [1,2-13 C]acetate, the labeling of glutamine from [1-13 C]glucose remained at 42% of control (Table 2) . Fluoroacetate did not, however, cause a significant re duction in the labeling of glutamate C-4 from [1-13 C]glucose, but it reduced the glutamine C-4/glutamate C-4 enrichment ratio obtained with [l-13 C]glucose from 0.54 ± 0.04 to 0.29 ± 0. 12 (P < 0.001). The enrichment of GABA C-2 from [l-13 C]glucose was reduced by 33%
with marginal significance (P = 0.08) in the presence of fluoroacetate. The labeling of aspartate C-2 and C-3 from [1-l3 C]glucose was not significantly reduced by flu oro acetate (Tables 2 through 4 ). However, in fluoroacetate treated animals, aspartate C-2 was more highly enriched than the C-3 (P = 0.0 1, paired Student's t-test).
The C-3/C-4 enrichment ratios in glutamate and glu tamine are indices of the number of times that the l3 C has passed through a TCA cycle (Hassel et aI., 1995; Hassel and Sonnewald 1995a) . During fluoroacetate treatment the C-3/C-4 enrichment ratios in glutamate and gluta mine were 0.27 ± 0.05 and 0.55 ± 0.15, respectively. These values were significantly different (P = 0.008, paired Student's t-test), indicating that the 13 C in gluta mine had cycled more in a TCA cycle than the 13 C in glutamate. The C-3/C-2 enrichment ratio in GABA (0.51 ± 0.33) was not significantly different from the corre sponding C-3/C-4 enrichment ratios in either glutamine or glutamate.
The percent enrichment of glucose C-l increased 123%, from approximately 30% to approximately 67% small doublet, with one peak on each side of the GABA C-3 peak (Fig. 1) . A peak corresponding to citrate C-2 + C-4 was also clearly visible in these brains. However, no peak corresponding to citrate C-3 was seen, indicating that the label in the accumulated citrate had not passed a full turn through the TCA cycle. The two animals that convulsed during fluoroacetate exposure did not stand out with respect to percent enrichment of any metabolite. To determine whether tluoroacetate blocked the up take of [1,2-l3 C]acetate, a separate experiment was per formed in which [1,2- l3 C]acetate and unlabeled glucose was given intravenously to fluoroacetate-treated animals and controls. Analysis by GC/MS showed that double labeling of cerebral citrate was unaffected by fluoroac etate, whereas the double labeling of glutamine was re duced by ","90% (Table 4 ). This confirms that [1,2-J3 C]acetate was taken up and converted to citrate, and that the metabolic block caused by fluoroacetate was distal to the formation of citrate, but before the formation of glutamine. The identity of the double-labeled gluta mine in control animals as predominantly representing [4,5-l3 C]glutamine was verified by l3 C NMR spectros copy (Fig. 1) . The percent enrichment of glutamine C-4 was 9.5% ± 1.8% as determined from the [4,5-13 C]isotopomer of glutamine.
Lactate C-2 was present as a small doublet ( Fig. I) representing an enrichment of 0.3% ± 0.07% as deter mined by J3 C NMR spectroscopy. This was confirmed by GC/MS, which showed 0.4% ± 0.2% doubly labeled lactate. No labeling of lactate was seen in the presence of fluoroacetate.
DISCUSSION
In the present study glial-neuronal interactions were identified by simultaneously introducing 13 C into the glial and neuronal TCA cycles with [I ,2-13 C]acetate and [1-13 C]glucose, respectively. The glial metabolism of [1,2-J3 C]acetate and the predominantly neuronal me tabolism of [1-l3 C]glucose was confirmed by the result ing glutamine/glutamate enrichment ratios being greater and less than one, respectively (O'Neal and Koeppe, 1966; Van den Berg et aI., 1969; Hassel et aI., 1992) , which reflects the strictly glial localization of glutamine synthetase (Martinez-Hernandez et aI., 1977) . These in dices of metabolic compartmentation, originally defined by amino acid labeling by trace amounts of radiolabel, were thus maintained even with the large amounts of 13 C-containing substrates used in the current study. The glial metabolism of acetate was further demonstrated by the effect of fluoroacetate, which blocked the formation of [4,5-l3 C]glutamine from [1,2-13 C]acetate almost com pletely, but had little effect on the formation of [4-J 3 C]glutamate and [2-13 C]GABA from [1-J 3 C]glucose. The latter observation confirms that fluoroacetate did not interfere with the neuronal TCA cycles. During fluoro acetate treatment the formation of [1,2-I3 C]GABA was abolished even though the neuronal TCA cycles were not inhibited by fluoroacetate. This shows that acetate is not a substrate for neurons, and that [ J 3 C]acetate may be used as a highly specific marker for glial metabolism in the high doses needed for 13 C NMR spectroscopy. Glutamine 11.4 ± 1.7 1.4± 1.3* Animals were dosed intravenously with [I,2-1 3 C]acetate and [ 1 2 C]glucose in the same injection (both 0.5 moUL, 0.3 mL), and were killed at 15 minutes. One group of animals received fluoroacetate, 100 mg/kg, intraperitoneally 15 minutes before the [ I' C] and [ 1 2 C] sub strates. Brain extracts were analyzed by GC/MS. Values represent double IJ C-labeled citrate and glutamine as percent of total citrate and glutamine, mean ± SO. * Different from control, P = 6 x 10-6 ; Stu dent's t-test.
A notable finding in the present study was the labeling of glutamine from [1_ 13 C]glucose during fluoroacetate treatment. This was intriguing since the glial TCA cycle was inhibited, and the labeling of glutamine from [1,2-J 3 C]acetate was blocked. The neuronal TCA cycles were not inhibited by fluoroacetate, however, and the [4-l3 C]glutamine was probably formed from glutamate that was labeled from [l-13 C]glucose in neurons, released during neurotransmission, and subsequently taken up by glia. This indicates considerable glial uptake and inacti vation of neuronal, i.e., transmitter, glutamate. This also shows that glucose, and not only glutamine, may label endogenous transmitter glutamate.
From the foregoing it appears that two pools of glu tamate serve as quantitatively important precursors for glutamine, the glial pool and the neuronal transmitter pool. The latter is quantitatively important, because in the present study approximately 40% of the [4-13 C]glutamine formed from [1-J3 C]glucose was derived from glutamate released from neurons. Distinguishing between the various pools of glutamate serving as pre cursors for glutamine may become important with the clinical use of J3 C NMR spectroscopy. For instance, in brain areas of neurodegeneration and gliosis, the astro cytic pool of glutamate will probably be of greater im portance for glutamine synthesis than the transmitter pool. Another interesting finding was the higher C-3/ C-4 enrichment ratio in glutamine than in glutamate during fluoroacetate treatment. The C-3/C-4 enrichment ratio is an index of the average number of times that the label has cycled in a TCA cycle (Hassel et aI., 1995; Hassel and Sonnewald 1995a) . In the presence of fluoroacetate, be cause the labeling of glutamine from [1-13 C]glucose can only be explained by glial uptake of neuronally released glutamate, this glutamate must have had a higher C-3/ C-4 enrichment ratio than average, indicating that it was associated with a TCA cycle that turned more rapidly than the overall cerebral TCA cycle. This agrees with previous findings that the transmitter pool of glutamate turns over more rapidly than the nontransmitter, or meta bolic, pool of glutamate (Cotman and Hamberger, 1978; Engelsen et aI., 1986) . The fluoroacetate-induced block ade of the glial TCA cycle prevented cycling of label in glia, which could otherwise have explained the differ ence in the C-3/C-4 enrichment ratio. It should be em phasized that [2-13 C]GABA, being a four-carbon mol ecule, must pass through the glial TCA cycle before its label can be transferred to glutamine. This would lead to labeling of glutamine C-2 and C-3, but not of the C-4. In the presence of fluoroacetate, however, this probably did not occur because of the inhibition of the glial TCA cycle.
The conclusion that acetate is not a sUDstrate for GA BAergic neurons implies that [1 ,2-13 C] acetate labeled GABA by some glial metabolite that was able to label GABA in the C-l and C-2 positions. Such labeling re quires that the glial precursor of GAB A is a five-or a six-carbon molecule. This is because GABA cannot be formed directly from a four-carbon molecule by reversal of succinic semialdehyde dehydrogenase and GABA transaminase (Mohler et a!., 1974) . Therefore, four carbon molecules like malate and succinate, which were suggested to be transferred from glia to neurons (Shank and Campbell., 1984; Westergaard et aI., 1994) , could not explain the formation of [1,2-13 C]GABA. Citrate, 2-oxoglutarate, and glutamine are the five-and six carbon metal50lites that are released by astrocytes (Son new aId et aI., 1991; Westergaard et aI., 1994; Hassel et aI., 1994) . The level of citrate in the cerebrospinal fluid is 0.3 to 0.6 mmollL, similar to the level of glutamine (Petroff et aI., 1986), but its physiologic role remains unknown. Citrate has been suggested as a substrate for neurotransmitter synthesis (Sonnewald et a!., 1991) . In the present study fluoroacetate blocked the labeling of glutamate and GABA from [1,2-13 C]acetate, whereas the labeling of glial citrate was preserved. This shows that endogenous glial citrate is not a substrate for neurons in vivo. Previously, radiolabeled citrate and 2-oxoglutarate have been shown to be taken up by glial cells and not by neurons after intracerebral injection in vivo (Hassel et aI., 1992) . The only glial metabolite that could explain the labeling of GABA seen in the present study is, therefore, glutamine.
Glucose accumulated in the brains of fluoroacetate treated animals as seen from the increase in the cerebral pool size and percent enrichment of glucose in fluoroac etate-treated animals, although serum glucose was main tained at control level. This accumulation could reflect the inhibitory effect of citrate on phosphofructokinase (Garland et aI., 1963) , which would inhibit glial glycol ysis. The overall neuronal glycolytic rate was not re duced, however, because the percent enrichment of lac tate and alanine from [1-13 C]glucose was the same in fluoroacetate-treated animals and controls. The block in the glial metabolism of [1-13 C]glucose to [4-13 C] J Cereb Blood Flow Metob. Vol. 17, No. II, 1997 glutamine could fully account for the reduction in the labeling of GABA C-2.
[l,2-13 C]Acetate labeled lactate in controls, but not during fluoroacetate treatment. This confirms a recent observation that glial cells may convert TCA cycle in termediates into pyruvate and lactate in vivo (Hassel and Sonnewald, 1995b) .
Treatment with fluoroacetate led to an increase in the level of citrate in agreement with conversion of fluoro acetate into fluorocitrate, which is an inhibitor of aconi tase (Peters, 1957) . The increase in citrate compared well with the reduction in aspartate, which suggests that glial aspartate was converted to oxaloacetate and consumed in the synthesis of citrate. The reduction in aspartate im plies stoichiometric formation of glutamate by the aspar tate aminotransferase reaction. However, the level of glutamate was decreased by fluoroacetate, whereas the level of alanine increased. This indicates catabolism of glutamate in the alanine aminotransferase reaction. The observation that the decrease in aspartate was near stoichiometric with the increase in alanine suggests that the two aminotransferases operate in a concerted manner to regulate the level of TCA cycle intermediates and related amino acids. As mentioned in Methods, [1,2-13 C]aspartate and [3,4_ 13 C]aspartate were probably la beled from [1 ,2_ 1 3 C]acetate, and not by cycling of the label from [1-13 C]glucose, as [I ,2-13 C] aspartate and [3,4-13 C]aspartate were not present in fluoroacetate treated animals, whereas the levels of [2-13 C]aspartate and [3-13 C]aspartate were similar in fluoroacetate-treated animals and controls. In controls aspartate C-2 and C-3 were equally well enriched from [1-13 C]glucose. Inter estingly, with fluoroacetate the aspartate C-2 became more highly enriched than the C-3. This could reflect incomplete scrambling of label in the neuronal TCA cycle. It may be that glial pyruvate carboxylation, which leads to preferential labeling of aspartate C-3 from [1-13 C]glucose masks this phenomenon in the control situ ation.
The lack of effect of fluoroacetate on the labeling of lactate, alanine, glutamate, GABA, and aspartate from [1-13 C]glucose shows that neuronal glycolysis and TCA cycle activity remained unaffected by the toxin. This should, however, not be taken to indicate that neuronal electrical activity was not affected by the fluoroacetate. As has been shown previously, fluorocitrate, the toxic product of fluoroacetate, affects neuronal activity by in terfering with astrocytic maintenance of extracellular po tassium homeostasis and pH (Largo et aI., 1996) . In the current study, such indirect effects of fluoroacetate on neuronal activity were illustrated by the behavioral changes in the treated animals.
The high percent enrichment of glutamine from [1,2-13 C]acetate, which was higher than that of glutamate from [l-13 C]glucose, suggests that I3 C-Iabeled acetate would be as suitable a substrate as [l-13 C]glucose (Gru etter et aI., 1994; Mason et aI., 1995) for in vivo studies in humans. [ 13 C]Acetate has the advantage of yielding high enrichments of cerebral amino acids in spite of high serum levels of glucose (Hassel and Sonnewald, 1995b;  this study). Therefore, glucose clamping with insulin is not necessary during infusion of [ 13 C]acetate. The use of
[ 13 C]acetate should be thought of as complementary to the use of [ 13 C]glucose, because [ 13 C]acetate elucidates glial metab.olism and glial-neuronal interactions which do not become apparent with [ 13 C]glucose alone.
In conclusion, the present study gives in vivo evidence that [ 13 Clacetate given in large amounts is metabolized by glia and not by neurons, and that [ 13 C]acetate labels GABA through glutamine. Furthermore, endogenous neuronal glutamate is to a large extent taken up by glial cells and converted to glutamine. This demonstrates the validity of the concept of a glutamine-glutamate cycle in the brain in vivo.
